Application of radix astragali extract

Abstract

The invention relates to an application of an extract of a medicinal natural product, in particular to an application of a radix astragali extract. The natural product extract disclosed by the invention is an extract of radix astragali, especially total flavonoids of radix astragali or astragaloside. The radix astragali extract disclosed by the invention can be directly used for preparing the medicine for treating the pulmonary fibrosis disease or used for preparing the compound medicine for treating the pulmonary fibrosis disease. The invention has the following beneficial effects: 1, it is found for the first time that total flavonoids of radix astragali and astragaloside can inhibit polarization of M2 type macrophages and activation of TGF-beta1 / Smads signal channels, and effectively inhibit pulmonary fibrosis; and 2, the medicine is a traditional Chinese medicinal material, is low in price and small in toxic and side effects, can remarkably inhibit the development of pulmonary fibrosis, and is worthy of wide popularization.

Description

technical field [0001] The present invention relates to the use of an extract of a medicinal natural product, specifically, the present invention relates to the use of an extract of Astragalus membranaceus. Background technique [0002] Astragalus membranaceus is a traditional Chinese medicinal material, which contains saponins, flavonoids, polysaccharides, trace elements and other components, and has anticancer, hepatoprotective, antibacterial and antiviral, antioxidative, anticonvulsant and neuroprotective effects. [0003] Pulmonary fibrosis is a chronic and progressive pulmonary interstitial disease. The main pathological changes are pulmonary inflammatory cell infiltration, abnormal deposition of cell matrix, and excessive proliferation of fibroblasts accompanied by alveolar structural destruction, and gradually lead to pulmonary ventilation. Function declines, and eventually most patients die of respiratory failure caused by diffuse pulmonary fibrosis. At present, it ...

AI Technical Summary

Problems solved by technology

These two drugs have shown good efficacy in numerous clinical trials, but they are not suitable for all patients with pulmonary fibrosis, and may cause adverse reactions of varying degrees, such as nintedanib can cause diarrhea, Adverse reactions such as nausea and vomiting, abdominal pain, loss of appetite, weight loss and elevated liver enzymes, pirfenidone can cause symptoms such as nausea and vomiting, photosensitivity, liver function damage and lethargy in patients

In addition, although the treatment of acute exacerbation of pulmonary fibrosis with glucocorticoids, oxygen supply, mechanical ventilation, pulmonary rehabilitation, anti-pulmonary hypertension treatment, and lung transplantation may be effective for some patients or for short-term symptom relief, in order to prolong the duration of the disease To increase the survival time of more patients with pulmonary fibrosis and reduce the mortality rate of the disease, the research and development of the pathogenesis of pulmonary fibrosis and related drugs still needs to make persistent efforts

Images